Brief: Incyte Announces Positive Topline Results From Study Of Tafasitamab

Incyte

05/01/2026 14:15

Jan 5 (Reuters) - Incyte Corp INCY.O:

INCYTE ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL STUDY OF TAFASITAMAB (MONJUVI®/MINJUVI®) AS A FIRST-LINE TREATMENT FOR DIFFUSE LARGE B-CELL LYMPHOMA

INCYTE - PHASE 3 FRONTMIND TRIAL MEETS PRIMARY ENDPOINT OF PFS

INCYTE - PLANS TO FILE SBLA FOR TAFASITAMAB IN 2026

INCYTE - TRIAL MEETS SECONDARY ENDPOINT OF EVENT-FREE SURVIVAL

INCYTE: EXPECTS TO FILE A SBLA FOR TAFASITAMAB FOR FIRST-LINE TREATMENT OF ADULTS WITH NEWLY DIAGNOSED DLBCL IN H1 2026

Source text: ID:nBw35KXBqa

Further company coverage: INCY.O

 ((Reuters.Briefs@thomsonreuters.com;))